Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37803333)

  • 1. Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
    Vincent CA; Nissen I; Dakhel S; Hörnblad A; Remeseiro S
    BMC Cancer; 2023 Oct; 23(1):945. PubMed ID: 37803333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
    Bassi R; Dei Cas M; Tringali C; Compostella F; Paroni R; Giussani P
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
    BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion.
    Ding Z; Roos A; Kloss J; Dhruv H; Peng S; Pirrotte P; Eschbacher JM; Tran NL; Loftus JC
    Mol Cancer Res; 2018 Feb; 16(2):322-332. PubMed ID: 29117939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
    Areeb Z; Stuart SF; West AJ; Gomez J; Nguyen HPT; Paradiso L; Zulkifli A; Jones J; Kaye AH; Morokoff AP; Luwor RB
    Sci Rep; 2020 Oct; 10(1):17768. PubMed ID: 33082482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
    Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
    Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of temozolomide on apoptosis-related gene expression changes in glioblastoma cells.
    Vidomanova E; Majercikova Z; Dibdiakova K; Pilchova I; Racay P; Hatok J
    Bratisl Lek Listy; 2022; 123(4):236-243. PubMed ID: 35294208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
    She L; Gong X; Su L; Liu C
    Oncologist; 2023 Jan; 28(1):e45-e53. PubMed ID: 36181764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
    Reinhardt LS; Morás AM; Henn JG; Arantes PR; Ferro MB; Braganhol E; de Souza PO; de Oliveira Merib J; Borges GR; Dalanhol CS; de Barros Dias MCH; Nugent M; Moura DJ
    Int J Pharm; 2022 Apr; 617():121584. PubMed ID: 35202726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
    Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
    Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma.
    Cui X; Zhao J; Li G; Yang C; Yang S; Zhan Q; Zhou J; Wang Y; Xiao M; Hong B; Yi K; Tong F; Tan Y; Wang H; Wang Q; Jiang T; Fang C; Kang C
    Cancer Commun (Lond); 2023 Dec; 43(12):1326-1353. PubMed ID: 37920878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
    Banstola A; Duwa R; Emami F; Jeong JH; Yook S
    Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
    Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
    Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
    Munoz JL; Rodriguez-Cruz V; Greco SJ; Ramkissoon SH; Ligon KL; Rameshwar P
    Cell Death Dis; 2014 Mar; 5(3):e1145. PubMed ID: 24675463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.